Lv2
160 积分 2022-08-23 加入
Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial
1天前
待确认
Adjuvant transarterial chemoembolization for hepatocellular carcinoma following curative resection: A randomized, open-label, phase 3 trial
2天前
已完结
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
3天前
已完结
Immune checkpoint inhibitors and the liver: balancing therapeutic benefit and adverse events
3天前
已完结
New advances in the study of PD-1/PD-L1 inhibitors-induced liver injury
3天前
已完结
Small-molecule-based targeted therapy in liver cancer
8天前
已完结
Exploiting senescence for the treatment of cancer
8天前
已完结
Adjuvant transarterial chemoembolization for hepatocellular carcinoma following curative resection: A randomized, open-label, phase 3 trial
10天前
已完结
Elimination of Senescent Osteocytes by Bone‐Targeting Delivery of β‐Galactose‐Modified Maytansinoid Prevents Age‐Related Bone Loss
11天前
已完结
Different effects of dihydropyridine calcium channel antagonists on CYP3A4 enzyme of human liver microsomes
23天前
已完结
皖公网安备34019202002308
